May 27, 2025 01:04 PM EDT

FDA rejects Savara’s rare lung disease drug over limited manufacturing data

Anna Brown

News Reporter

The FDA has rejected Savara’s application for its rare lung disease candidate over insufficient chemistry, manufacturing and controls data, the clinical-stage biotech said Tuesday. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

FDA rejects Savara’s rare lung disease drug over limited manufacturing data

Anna Brown

News Reporter

Sign up to read this article for free.

Large pharma companies spell out reasons why tariffs will harm US investments

Supreme Court to keep mulling state PBM dispute as US urges justices to decline case

FDA rejects Stealth's rare disease drug, but offers potential for accelerated approval

Merck, Daiichi Sankyo scrap FDA application for HER3 ADC after survival miss

Intellia reports case of liver toxicity in ATTR gene editing study

From weeks to days: how Aizon Intelligent Agents transform pharma validation

FDA re­jects Savara’s rare lung dis­ease drug over lim­it­ed man­u­fac­tur­ing da­ta

Anna Brown

News Reporter

Sign up to read this article for free.

Large phar­ma com­pa­nies spell out rea­sons why tar­iffs will harm US in­vest­ments

Supreme Court to keep mulling state PBM dis­pute as US urges jus­tices to de­cline case

FDA re­jects Stealth's rare dis­ease drug, but of­fers po­ten­tial for ac­cel­er­at­ed ap­proval

Mer­ck, Dai­ichi Sankyo scrap FDA ap­pli­ca­tion for HER3 ADC af­ter sur­vival miss

In­tel­lia re­ports case of liv­er tox­i­c­i­ty in AT­TR gene edit­ing study

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

FDA rejects Savara’s rare lung disease drug over limited manufacturing data

Large pharma companies spell out reasons why tariffs will harm US investments

Supreme Court to keep mulling state PBM dispute as US urges justices to decline case

FDA rejects Stealth's rare disease drug, but offers potential for accelerated approval

Merck, Daiichi Sankyo scrap FDA application for HER3 ADC after survival miss

Intellia reports case of liver toxicity in ATTR gene editing study

From weeks to days: how Aizon Intelligent Agents transform pharma validation